Codrituzumab(Synonyms: GC33; RO5137382)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Codrituzumab (Synonyms: GC33; RO5137382)

Codrituzumab 是一种靶向 GPC3 (glypican-3) 的单克隆抗体。GPC3 是一种表达于肝细胞癌 (HCC) 细胞表面的癌胚蛋白。Codrituzumab 诱导抗体依赖性细胞毒性 (ADCC) 并抑制肿瘤生长。

Codrituzumab(Synonyms: GC33; RO5137382)

Codrituzumab Chemical Structure

CAS No. : 1365267-33-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth[1][2].

CAS 号

1365267-33-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Mika Endo, et al. Abstract 2747: Anti-glypican-3 monoclonal antibody (codrituzumab/GC33/RO5137382) treatment enhances tumor infiltration of PD-L1-positive macrophages, and combination therapy with anti-PD-L1 monoclonal antibody promotes antitumor effects. Cancer Res (2018) 78 (13_Supplement): 2747.

    [2]. Chen G, et al. Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab. Oncotarget. 2018 Jan 2;9(12):10436-10444.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务